Curis to Release Third Quarter 2012 Financial Results and Hold Conference Call on November 6, 2012

Curis, Inc. Logo

LEXINGTON, Mass., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will release its third quarter financial results on Tuesday, November 6, 2012, before the market opens. The Company will also hold a conference call on the same day at 9:00 A.M. Eastern time to discuss: (i) Erivedge™ (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech, (ii) CUDC-101, CUDC-907 and Debio 0932 (iii) its financial results as of and for the three- and nine-month periods ended September 30, 2012, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 9:00 A.M. Eastern Time. The conference ID number is 41203077. The conference call can also be accessed on the Curis website at in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. Eastern Time, Monday, November 12, 2012. To access the replay, please call (855) 859-2056 from the United States or (404) 537-3406 from other locations and reference the conference ID number 41203077.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at

The Curis, Inc. logo is available at

CONTACT: For More Information: Michael P. Gray CFO & COO Curis, Inc. 617-503-6632

Source:Curis, Inc.